Heska Corp (HSKA) Position Lowered by GSA Capital Partners LLP

GSA Capital Partners LLP decreased its stake in Heska Corp (NASDAQ:HSKA) by 49.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,505 shares of the medical research company’s stock after selling 13,200 shares during the period. GSA Capital Partners LLP owned approximately 0.19% of Heska worth $1,190,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Royal Bank of Canada lifted its stake in shares of Heska by 96.9% in the second quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock valued at $103,000 after purchasing an additional 499 shares during the period. SG Americas Securities LLC bought a new stake in shares of Heska in the third quarter worth $108,000. Victory Capital Management Inc. increased its stake in shares of Heska by 17.5% in the second quarter. Victory Capital Management Inc. now owns 1,133 shares of the medical research company’s stock worth $116,000 after buying an additional 169 shares during the last quarter. Municipal Employees Retirement System of Michigan bought a new stake in shares of Heska in the second quarter worth $154,000. Finally, BNP Paribas Arbitrage SA increased its stake in shares of Heska by 59.2% in the second quarter. BNP Paribas Arbitrage SA now owns 1,858 shares of the medical research company’s stock worth $190,000 after buying an additional 691 shares during the last quarter. Hedge funds and other institutional investors own 80.89% of the company’s stock.

A number of analysts recently issued reports on HSKA shares. B. Riley restated a “hold” rating and issued a $96.50 price target on shares of Heska in a research note on Friday, October 27th. Canaccord Genuity assumed coverage on Heska in a report on Thursday, October 5th. They set a “buy” rating and a $115.00 price objective on the stock. Raymond James Financial restated a “buy” rating on shares of Heska in a report on Monday, December 4th. BidaskClub downgraded Heska from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. Finally, Zacks Investment Research downgraded Heska from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $113.30.

In other news, insider Michael J. Mcginley sold 7,826 shares of the company’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total value of $681,957.64. Following the transaction, the insider now owns 106,771 shares in the company, valued at approximately $9,304,024.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 14.70% of the stock is currently owned by insiders.

Shares of Heska Corp (HSKA) opened at $80.98 on Friday. The stock has a market capitalization of $588.12, a PE ratio of 42.51, a price-to-earnings-growth ratio of 2.16 and a beta of 0.75. Heska Corp has a twelve month low of $70.49 and a twelve month high of $115.00.

Heska (NASDAQ:HSKA) last posted its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.03. The firm had revenue of $31.40 million for the quarter, compared to the consensus estimate of $36.10 million. Heska had a return on equity of 15.35% and a net margin of 10.67%. The business’s revenue for the quarter was down 6.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.45 EPS. equities research analysts forecast that Heska Corp will post 2.03 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Heska Corp (HSKA) Position Lowered by GSA Capital Partners LLP” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.com-unik.info/2017/12/23/heska-corp-hska-position-lowered-by-gsa-capital-partners-llp.html.

Heska Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).

Institutional Ownership by Quarter for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit